FDA to modernize drug surveillance internally with use of AI
BALTIMORE — The FDA is modernizing the way it surveils drugs after they come to market, employing new uses for AI with the help of humans, to mine the more than two million reports of adverse events that the agency receives each year.
The AI-based decision support tool that the agency is about to begin using internally — known as the Information Visualization Platform — was developed over the past decade, said Robert Ball, deputy director of FDA’s Office of Surveillance and Epidemiology, to attendees at a DIA pharmacovigilance conference. The tool will first be used to deploy a deduplication algorithm for the adverse event reports.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.